Thus, our findings highlight the potential for the pharmacological activation of the Nrf2/ARE antioxidant pathway, such as through the use of tBHQ as a therapeutic approach against oxidative stress and inflammation in CKD patients with hyperlipidemia. The gene discussed is NFE2L2; the disease is chronic kidney disease.